SG11201901449XA - Method for treating pruritus and/or itch - Google Patents
Method for treating pruritus and/or itchInfo
- Publication number
- SG11201901449XA SG11201901449XA SG11201901449XA SG11201901449XA SG11201901449XA SG 11201901449X A SG11201901449X A SG 11201901449XA SG 11201901449X A SG11201901449X A SG 11201901449XA SG 11201901449X A SG11201901449X A SG 11201901449XA SG 11201901449X A SG11201901449X A SG 11201901449XA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- pct
- itch
- treating pruritus
- english
- Prior art date
Links
- 208000003251 Pruritus Diseases 0.000 title abstract 6
- 239000003814 drug Substances 0.000 abstract 2
- 239000013543 active substance Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A61K9/122—Foams; Dry foams
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Botany (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662378435P | 2016-08-23 | 2016-08-23 | |
| PCT/IB2017/053989 WO2018037295A1 (en) | 2016-08-23 | 2017-06-30 | Method for treating pruritus and/or itch |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201901449XA true SG11201901449XA (en) | 2019-03-28 |
Family
ID=59416750
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201901449XA SG11201901449XA (en) | 2016-08-23 | 2017-06-30 | Method for treating pruritus and/or itch |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20190175554A1 (enExample) |
| EP (1) | EP3503884B1 (enExample) |
| JP (1) | JP6910424B2 (enExample) |
| KR (1) | KR20190040298A (enExample) |
| CN (1) | CN109843286A (enExample) |
| AU (1) | AU2017315265C1 (enExample) |
| CA (1) | CA3033534A1 (enExample) |
| MX (1) | MX381311B (enExample) |
| SG (1) | SG11201901449XA (enExample) |
| TW (1) | TW201808269A (enExample) |
| WO (1) | WO2018037295A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7048051B2 (ja) * | 2018-07-11 | 2022-04-05 | 正徳 染井 | 痒みを軽減するアトピー性皮膚炎治療剤 |
| WO2021151059A1 (en) * | 2020-01-24 | 2021-07-29 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Compounds and methods for treating or reducing pruritus |
| EP4118070A4 (en) * | 2020-03-11 | 2024-04-10 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
| KR20240144096A (ko) | 2021-11-02 | 2024-10-02 | 플레어 테라퓨틱스 인크. | Pparg 역 효능제 및 그의 용도 |
| WO2024229352A2 (en) * | 2023-05-04 | 2024-11-07 | Caamtech, Inc. | Tryptamine derivatives |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5521183A (en) * | 1994-08-30 | 1996-05-28 | Allergan | Use of 5-HT ligands as anti-pruritic agents |
| US5972905A (en) * | 1995-06-14 | 1999-10-26 | Institute Of Immunology Co., Ltd. | Use of oligosaccharides for the treatment of pruritus cutaneus associated with renal failure |
| WO1997028793A1 (fr) * | 1996-02-07 | 1997-08-14 | Lead Chemical Co., Ltd. | Preparation a usage externe comprenant du tranilast et processus de production de cette preparation |
| CN1215835C (zh) * | 1996-03-27 | 2005-08-24 | 东丽株式会社 | 酮衍生物及其在医学上的应用 |
| JP2000327570A (ja) * | 1999-05-24 | 2000-11-28 | Nof Corp | 皮膚外用剤 |
| US6552073B1 (en) * | 2002-03-01 | 2003-04-22 | Exonhit Therapeutics Sa | Compounds and methods of treating cell proliferative diseases |
| US7635710B2 (en) * | 2006-02-15 | 2009-12-22 | Neurim Pharmaceuticals (1991) Ltd. | Pyrone-indole derivatives and process for their preparation |
| US9101613B2 (en) * | 2006-02-15 | 2015-08-11 | Neurim Pharmaceuticals (1991) Ltd. | Methods for treating neurological disease |
| JP5513705B2 (ja) * | 2006-03-29 | 2014-06-04 | 小林製薬株式会社 | 知覚過敏型肌掻痒感改善剤 |
| WO2008036979A2 (en) * | 2006-09-22 | 2008-03-27 | Guilford F Timothy | Topical application of melatonin directly or in liposomes for the amelioration of itching and histamine and non-histamine related inflammatory skin changes |
| KR101359078B1 (ko) * | 2011-03-08 | 2014-02-05 | 이홍식 | 자주색 산삼배양근의 제조방법 |
| CN105492430B (zh) * | 2013-03-15 | 2017-10-10 | 基因泰克公司 | 取代的苯并噁唑及其使用方法 |
| US9493429B2 (en) * | 2013-03-15 | 2016-11-15 | Genentech, Inc. | Substituted benzoxazoles and methods of use thereof |
-
2017
- 2017-06-30 WO PCT/IB2017/053989 patent/WO2018037295A1/en not_active Ceased
- 2017-06-30 CA CA3033534A patent/CA3033534A1/en not_active Abandoned
- 2017-06-30 US US16/324,707 patent/US20190175554A1/en not_active Abandoned
- 2017-06-30 MX MX2019002149A patent/MX381311B/es unknown
- 2017-06-30 CN CN201780052128.4A patent/CN109843286A/zh active Pending
- 2017-06-30 SG SG11201901449XA patent/SG11201901449XA/en unknown
- 2017-06-30 KR KR1020197008201A patent/KR20190040298A/ko not_active Ceased
- 2017-06-30 EP EP17745509.4A patent/EP3503884B1/en active Active
- 2017-06-30 JP JP2019506699A patent/JP6910424B2/ja active Active
- 2017-06-30 AU AU2017315265A patent/AU2017315265C1/en active Active
- 2017-08-02 TW TW106125990A patent/TW201808269A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20190040298A (ko) | 2019-04-17 |
| US20190175554A1 (en) | 2019-06-13 |
| AU2017315265A1 (en) | 2019-02-28 |
| AU2017315265C1 (en) | 2021-06-10 |
| AU2017315265B2 (en) | 2021-03-11 |
| EP3503884A1 (en) | 2019-07-03 |
| CN109843286A (zh) | 2019-06-04 |
| EP3503884B1 (en) | 2021-07-21 |
| WO2018037295A1 (en) | 2018-03-01 |
| TW201808269A (zh) | 2018-03-16 |
| MX381311B (es) | 2025-03-12 |
| JP6910424B2 (ja) | 2021-07-28 |
| JP2019524797A (ja) | 2019-09-05 |
| MX2019002149A (es) | 2019-09-18 |
| CA3033534A1 (en) | 2018-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
| SG11201900799XA (en) | Pyridopyrimdinone cdk2/4/6 inhibitors | |
| SG11201908391XA (en) | Methods for modulating an immune response | |
| SG11201811564QA (en) | Methods of treating ovarian cancer | |
| SG11201909949XA (en) | Targeted immunotolerance | |
| SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
| SG11201907034PA (en) | Methods of treating influenza | |
| SG11201807421TA (en) | The use of glucocorticoid receptor modulators to potentiate checkpoint inhibitors | |
| SG11201908420WA (en) | Compositions of plinabulin and use thereof | |
| SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
| SG11201407200TA (en) | Liquid formulation | |
| SG11201900883UA (en) | Combination treatment for hematological cancers | |
| SG11201804360XA (en) | Mat2a inhibitors for treating mtap null cancer | |
| SG11201808713YA (en) | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier | |
| SG11201901449XA (en) | Method for treating pruritus and/or itch | |
| SG11201810801QA (en) | Brain delivery protein | |
| SG11201909064RA (en) | Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer | |
| SG11201908159QA (en) | Dual magl and faah inhibitors | |
| SG11201900486WA (en) | Treatment and prevention of sleep disorders | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201910206QA (en) | Methods and compositions for treating inflammatory gastrointestinal disorders | |
| SG11201903786UA (en) | Farnesyltransferase inhibitors for use in methods of treating cancer | |
| SG11201903061YA (en) | Combination treatments comprising administration of imidazopyrazinones | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer |